Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Suspended 1

Sponsor Class

OTHER 22NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1

Conditions

Neoplasm Metastasis 2Ovarian Neoplasms 1Malignant Female Reproductive System Neoplasm 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Phantoms, Imaging 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × neratinib × 1 year × Clear all
NCT05564377 2026-06-12

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06126276 2026-06-11

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI)

Phase 1 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡